HRP20010133B1 - Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases - Google Patents

Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Info

Publication number
HRP20010133B1
HRP20010133B1 HR20010133A HRP20010133A HRP20010133B1 HR P20010133 B1 HRP20010133 B1 HR P20010133B1 HR 20010133 A HR20010133 A HR 20010133A HR P20010133 A HRP20010133 A HR P20010133A HR P20010133 B1 HRP20010133 B1 HR P20010133B1
Authority
HR
Croatia
Prior art keywords
treatment
optically active
vascular diseases
oxadiazine derivative
pyridyl
Prior art date
Application number
HR20010133A
Other languages
English (en)
Inventor
Jednakovits Andrea
Urogdi Laszlo
Denes Laszlo
Kurucz Istvan
Marvanyos Ede
Barabas Mihaly
Bacsy Erno
Korom Zsuzsanna
Nagy Zoltan
Urge Laszlo
Szilbereky Jenoe
Acsai Karoly
Krajcsi Peter
Csakai Zita
Toeroek Magdolna
Original Assignee
Biorex Kutat� �S Fejleszt� Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutat� �S Fejleszt� Rt. filed Critical Biorex Kutat� �S Fejleszt� Rt.
Publication of HRP20010133A2 publication Critical patent/HRP20010133A2/hr
Publication of HRP20010133B1 publication Critical patent/HRP20010133B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20010133A 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases HRP20010133B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
PCT/HU1999/000095 WO2000035914A1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
HRP20010133A2 HRP20010133A2 (en) 2002-02-28
HRP20010133B1 true HRP20010133B1 (en) 2005-02-28

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010133A HRP20010133B1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Country Status (27)

Country Link
US (1) US6384029B1 (OSRAM)
EP (1) EP1147105B1 (OSRAM)
JP (2) JP2002532498A (OSRAM)
KR (1) KR100661774B1 (OSRAM)
AT (1) ATE266027T1 (OSRAM)
AU (1) AU765336B2 (OSRAM)
BG (1) BG65179B1 (OSRAM)
BR (1) BR9913982A (OSRAM)
CA (1) CA2340734C (OSRAM)
CZ (1) CZ300764B6 (OSRAM)
DE (1) DE69917074T2 (OSRAM)
DK (1) DK1147105T3 (OSRAM)
EE (1) EE04551B1 (OSRAM)
ES (1) ES2219091T3 (OSRAM)
HR (1) HRP20010133B1 (OSRAM)
HU (1) HU226617B1 (OSRAM)
IL (1) IL141515A (OSRAM)
NO (1) NO317649B1 (OSRAM)
PL (1) PL196584B1 (OSRAM)
PT (1) PT1147105E (OSRAM)
RS (1) RS50129B (OSRAM)
RU (1) RU2222538C2 (OSRAM)
SI (1) SI1147105T1 (OSRAM)
SK (1) SK285582B6 (OSRAM)
UA (1) UA70340C2 (OSRAM)
WO (1) WO2000035914A1 (OSRAM)
ZA (1) ZA200101182B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2320330C2 (ru) 2002-01-11 2008-03-27 СиУайТиАрЭкс КОРПОРЕЙШН Производные карбоксамидина и их использование при лечении заболеваний сосудов
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
ES2385735T3 (es) 2008-06-26 2012-07-31 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
BRPI0919867A2 (pt) 2008-11-18 2015-12-15 Santen Pharmaceutical Co Ltd agente terapeutico ou profilatico para uma doenca degenerativa coriorretiniana, e metodo profilatico ou terapeutico para uma doenca degenerativa coriorrentiniana
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
DK3193840T3 (da) 2014-09-15 2021-08-16 Orphazyme As Arimoclomol-formulering
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
EP3630105A1 (en) 2017-05-24 2020-04-08 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
EP0858413B1 (en) * 1995-11-03 2003-05-21 Summit Packaging Systems Limited Apparatus for dispensing and filling bags at a checkout counter of a supermarket
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
DK1147105T3 (da) 2004-06-01
CZ20011550A3 (cs) 2001-08-15
AU1790600A (en) 2000-07-03
YU25001A (sh) 2004-07-15
PT1147105E (pt) 2004-07-30
EP1147105A1 (en) 2001-10-24
ATE266027T1 (de) 2004-05-15
HUP9802897A2 (hu) 2000-11-28
KR100661774B1 (ko) 2006-12-28
JP5620340B2 (ja) 2014-11-05
BG105342A (en) 2001-12-29
SK285582B6 (sk) 2007-04-05
NO20012310D0 (no) 2001-05-10
CZ300764B6 (cs) 2009-08-05
HU226617B1 (en) 2009-04-28
IL141515A (en) 2005-09-25
HRP20010133A2 (en) 2002-02-28
JP2002532498A (ja) 2002-10-02
SK2342001A3 (en) 2001-08-06
PL196584B1 (pl) 2008-01-31
KR20010073129A (ko) 2001-07-31
PL346767A1 (en) 2002-02-25
UA70340C2 (en) 2004-10-15
RS50129B (sr) 2009-03-25
EE04551B1 (et) 2005-10-17
NO317649B1 (no) 2004-11-29
EP1147105B1 (en) 2004-05-06
ES2219091T3 (es) 2004-11-16
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
ZA200101182B (en) 2002-02-12
AU765336B2 (en) 2003-09-18
JP2011201916A (ja) 2011-10-13
CA2340734A1 (en) 2000-06-22
DE69917074D1 (de) 2004-06-09
EE200100188A (et) 2002-08-15
DE69917074T2 (de) 2005-05-12
NO20012310L (no) 2001-05-10
BG65179B1 (bg) 2007-05-31
US6384029B1 (en) 2002-05-07
IL141515A0 (en) 2002-03-10
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
BR9913982A (pt) 2001-06-12
CA2340734C (en) 2008-10-21
WO2000035914A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
GB0005251D0 (en) Therapeutic compounds
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GR3015879T3 (en) Novel hydroxamic acid and n-hydroxyurea derivatives and their use.
HRP20010133B1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
BG106155A (en) Novel derivatives and analogues of galanthamin
IL109534A0 (en) Pour-on formulations containing polymeric material, glycols and glycerides and a process for their preparation
IL116384A0 (en) Ylidene compounds and their preparation
TR199901385T2 (xx) Piperidin t�revleri.
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
HUP9802896A3 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
DE69511247D1 (de) Therapeutische benzonitrile
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
GEP20002141B (en) Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease
TH32887A (th) สารประกอบทางเคมี

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20101124

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20111208